Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deffered Revenue: 2014-2025

Historic Non-Current Deffered Revenue for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $5.5 million.

  • CytomX Therapeutics' Non-Current Deffered Revenue fell 83.50% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 83.50%. This contributed to the annual value of $26.9 million for FY2024, which is 66.44% down from last year.
  • Per CytomX Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $5.5 million for Q3 2025, which was down 45.93% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Non-Current Deffered Revenue registered a high of $267.8 million during Q1 2021, and its lowest value of $5.5 million during Q3 2025.
  • Over the past 3 years, CytomX Therapeutics' median Non-Current Deffered Revenue value was $36.7 million (recorded in 2024), while the average stood at $61.7 million.
  • In the last 5 years, CytomX Therapeutics' Non-Current Deffered Revenue grew by 25.52% in 2021 and then tumbled by 83.50% in 2025.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Non-Current Deffered Revenue stood at $243.9 million in 2021, then decreased by 26.19% to $180.1 million in 2022, then plummeted by 55.54% to $80.0 million in 2023, then tumbled by 66.44% to $26.9 million in 2024, then crashed by 83.50% to $5.5 million in 2025.
  • Its Non-Current Deffered Revenue was $5.5 million in Q3 2025, compared to $10.2 million in Q2 2025 and $16.2 million in Q1 2025.